Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.43 |
| ▸ | PLK1 | P53350 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11746154 | 0.85 | TSHR (0.50) | MEN1KMT2ATSHRKDM4ENR1H2 | |
| SCHEMBL1059610 | 0.84 | TSHR (0.48) | MEN1KMT2ATSHRKDM4ENR1H2 | |
| SCHEMBL11498434 | 0.82 | TSHR (0.47) | MEN1KMT2ATSHRKDM4ENR1H2 | |
| SCHEMBL10890108 | 0.82 | TSHR (0.47) | MEN1KMT2ATSHRKDM4ENR1H2 | |
| SCHEMBL11677887 | 0.81 | TSHR (0.55) | MEN1KMT2ATSHRNPY1RNPY2R | |
| SCHEMBL14000141 | 0.79 | TSHR (0.52) | MEN1KMT2ATSHRNR1H2NR1H3 | |
| SCHEMBL9857416 | 0.79 | TSHR (0.52) | MEN1KMT2ATSHRNR1H2NR1H3 | |
| SCHEMBL1059031 | 0.79 | MAPT (0.46) | MEN1KMT2ATSHRNR1H2NR1H3 | |
| SCHEMBL11409747 | 0.78 | TSHR (0.43) | MEN1KMT2ATSHRKDM4ENR1H2 | |
| SCHEMBL11505275 | 0.78 | TSHR (0.43) | TSHRKDM4ENR1H2NR1H3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097626-A2 | COMPOUNDS AND METHODS RELATING THERETO | PHARMALUCIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306576-A1 | COMPOUNDS AND METHODS RELATING THERETO | QSOX1, PYM1, SQOR | MEN1 1604/4885KMT2A 3083/4885TSHR 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.